Ewan Hunter, Chief Data Officer at Oxford BioDynamics Plc, joins GCS CEO David Bloxham on the GCS Connect Leader Series to unpack how 3D genome "loops," epigenetics, and precise biomarker discovery are moving from sci fi to clinical reality. You'll hear how Oxford BioDynamics uses algorithmic "anchor points" (think GPS for the genome) to cut cost and time vs. blind discovery and how this translates into real-world impact like reducing PSA false positives in prostate cancer screening and predicting response